Senseonics (NYSE:SENS) announced today an underwritten offering of $50 million in 5.25% convertible senior notes due 2023, alongside a 30-day option for underwriters to buy up to an additional $7.5 million in notes to cover over-allotments. The notes, which mature on Feb. 1, 2023, will be convertible into shares of Senseonics’ common stock at approximately $3.40 […]
Senseonics
Senseonics tops sales estimates with Q3 results
Shares in Senseonics (NYSE:SENS) fell today even though the medical technology company beat expectations on Wall Street with its third quarter results. The Germantown, Md.-based company posted a loss of -$17.4 million on sales of $2.1 million for the 3 months ended Sept. 30. Adjusted to exclude 1-time items, earnings per share were -13¢, in-line […]
Senseonics wins CE Mark for Eversense XL glucose monitor
Senseonics (NYSE:SENS) said yesterday that it won CE Mark approval in the European Union for its Eversense XL continuous glucose monitor. The Eversense XL includes a glucose sensor designed to be implanted for 180 days and a removable smart transmitter that links with a mobile app for real-time glucose monitoring. Germantown, Md.-based Senseonics touts the sensor […]
Senseonics inks artificial pancreas deal with Roche, TypeZero Technologies
Senseonics (NYSE:SENS) said today that it inked a collaboration with TypeZero Technologies and Roche (OTC:RHHBY) Diabetes Care to develop an automated insulin delivery system. The deal is part of an NIH-funded effort to test artificial pancreas systems. The trial is slated to integrate Senseonic’s Eversense glucose monitor, TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight insulin pump. […]
Senseonics prices $41m underwritten offering for Eversense CGM
Senseonics (NYSE:SENS) said today that it priced an underwritten offering of 29 million shares of common stock at $1.41 apiece to a group of institutional investors. Roche (PINK:RHHBY) agreed to purchase 21 million shares and New Enterprise Associates agreed to purchase 7 million shares in the offering, according to the Germantown, Md.-based company. Senseonics said […]
Senseonics, TypeZero ink development deal for artificial pancreas
Senseonics (NYSE:SENS) said yesterday that it inked a non-exclusive R&D license agreement with TypeZero Technologies to develop artificial pancreas and decision support systems for its Eversense continuous glucose monitor. The companies plan to integrate glucose readings from the Eversense system with TypeZero’s inControl artificial pancreas algorithms to regulate insulin delivery through a user’s insulin pump. […]
Senseonics draws 3rd $5m tranche for implantable CGM
Senseonics (NYSE:SENS) said last month that it drew the 3rd installment of $5 million under its term loan facility with Oxford Finance and Silicon Valley Bank. The 3rd tranche, which closed on March 29 this year, was triggered by the 1st sale of the Germantown, Maryland-based company’s 2nd-gen transmitter in Europe. Senseonics previously borrowed $20 million […]
Roche denies rumors it will shop diabetes unit, earnings
Roche (PINK:RHHBY) denied rumors that it was considering selling its diabetes unit today, saying that it is “committed” to the business. The company also predicted that competition and spending on new drugs would stall its margin growth in 2017, as patents expire for its blockbuster medications. The Swiss drugmaker’s 3 top-selling cancer drugs, Rituxan, Herceptin and […]
Dexcom surges on Medicare nod for continuous glucose monitors
DexCom (NSDQ:DXCM) said yesterday that the Centers for Medicare & Medicaid classified therapeutic continuous glucose monitors as durable medical equipment under Medicare Part B. The company’s Dexcom G5 Mobile is the only CGM system that falls under this classification, according to San Diego, Calif.-based DexCom, since patients can make treatment decisions using the device. DXCM […]
Senseonics, Roche expand distribution deal for Eversense glucose monitor
Senseonics (NYSE:SENS) said today that it expanded its exclusive distribution agreement with Roche (PINK:RHHBY) for its implantable continuous glucose monitoring system for people with diabetes. The new agreement includes all of Europe, the Middle East and Africa, excluding Scandinavia, Finland and Israel. According to the agreement, Germantown, Maryland-based Senseonics has given Roche exclusive rights to promote, […]
